PCN42 COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS- A GERMAN HOSPITAL PERSPECTIVE
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65200-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)65200-X/fulltext
Section Title :
Section Order :
359
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65200-X&doi=10.1016/S1098-3015(10)65200-X